Elicio Therapeutics, Inc. quarterly report, Q1 FY2022

Business context and reporting period

Important filing-identity discrepancy: The supplied filing is Angion Biomedica Corp.’s Form 10-Q, not an Elicio Therapeutics, Inc. filing. It covers the quarter ended March 31, 2022, and reports Angion’s results.

Angion is a clinical-stage biopharmaceutical company focused on small-molecule therapies for acute organ injury and fibrotic diseases. Its primary development focus shifted to ANG-3070 after disappointing ANG-3777 trial results.

Key financial metrics

Amounts below are in millions of dollars except per-share data.

Revenue was contract revenue under the Vifor ANG-3777 license; Angion had no approved products or product-sale revenue. The filing does not provide a meaningful operating margin for this loss-making development-stage business.

Cash and cash equivalents were $73.002 million at March 31, 2022, down from $88.756 million at December 31, 2021. Total assets were $81.258 million, total liabilities $14.056 million, and stockholders’ equity $67.202 million. Accumulated deficit was $229.375 million. The company had no convertible notes outstanding; it reported a $0.279 million financing obligation and operating lease liabilities of $4.154 million.

Material changes versus the prior comparable period

• Revenue increased 344%, primarily because Angion reassessed the Vifor license performance period and estimated completion costs after deciding not to continue the planned ANG-3777 development program. Remaining deferred revenue was expected to be recognized by the end of 2022.
• R&D expense decreased 18% and G&A expense decreased 26%, largely reflecting lower personnel costs and reduced ANG-3777 trial activity, partly offset by severance and increased ANG-3070 development costs.
• Net loss narrowed substantially, largely because Q1 2021 included noncash fair-value and interest expenses associated with convertible notes, preferred stock, and warrants that were mostly no longer outstanding after the 2021 IPO.
• Operating cash use increased by $3.102 million year over year. Q1 2021 financing inflows included IPO and concurrent private-placement proceeds; Q1 2022 had no comparable capital raise.

Outlook, commentary, risks, and unusual items

• Management said existing cash was expected to fund planned operations for at least 12 months after issuance of the statements and well into 2023. It also cautioned that projections rely on assumptions and that additional capital may be required.
• ANG-3070 was the primary clinical focus, with enrollment ongoing in a Phase 2 dose-finding trial in primary proteinuric kidney diseases. On May 12, 2022, after quarter-end, the FDA accepted its IND for idiopathic pulmonary fibrosis and cleared a Phase 1b study; topline data were expected in 2022.
• ANG-3777’s Phase 3 delayed-graft-function trial and Phase 2 cardiac-surgery-associated acute-kidney-injury trial missed their primary endpoints. Angion did not plan further trials under the existing Vifor development plan and did not expect further related milestones or royalties. The parties continued to analyze trial results and discuss the collaboration.
• A January 2022 reduction in force affected somewhat less than half of employees. Related termination costs were approximately $3.2 million; $1.1 million was paid in the quarter and $2.1 million remained payable, primarily accrued.
• Key risks include clinical and regulatory failure, financing needs, COVID-19 and geopolitical disruption to trials in Eastern Europe, and dependence on third-party manufacturers and contractors. The company reported no material legal proceedings.
• Management concluded disclosure controls were ineffective at March 31, 2022 due to material weaknesses involving technical U.S. GAAP expertise and financial close/accrual controls. Remediation was ongoing; management said additional procedures supported fair presentation of the financial statements.

Important facts for investors to verify

1. Confirm the intended issuer: this source is Angion Biomedica Corp. (ticker ANGN), not Elicio Therapeutics, Inc.
2. Review the status and results of the ANG-3070 Phase 2 kidney trial and the subsequent IPF Phase 1b study.
3. Verify cash runway assumptions, quarterly cash burn, and the timing and terms of any future financing.
4. Track the Vifor collaboration’s outcome and whether any further revenue, milestones, or royalties are realistically expected.
5. Assess progress in remediating the disclosed material weaknesses in internal controls.